Adaptive biotechnologies stock.

Adaptive Biotechnologies Corp stock performance at a glance. Check Adaptive Biotechnologies Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. ADPT Stock Performance. USD USD; Previous close: 4.38: 4.38: Day range: 4.21 - 4.774.21 - 4.77Year range:Future price of the stock is predicted at 0$ (-100% ) after a year according to our prediction system. This means that if you invested $100 now, your current ...Jun 2, 2023 · Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ... Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...

Nov 2, 2023 · Stock. Stock Quote & Chart ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune ... Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Adaptive Biotechnologies Next up, Wood has been leaning into a leader in a rapidly emerging field. Adaptive Biotechnologies is a pioneering commercial-stage biotech company at the forefront of ...

Adaptive Biotechnologies Corp stock performance at a glance. Check Adaptive Biotechnologies Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. ADPT Stock Performance. USD USD; Previous close: 4.38: 4.38: Day range: 4.21 - 4.774.21 - 4.77Year range:About Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune ...

On average, Wall Street analysts predict. that Adaptive Biotechnologies's share price could reach $8.00 by Nov 13, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 83.07% from …Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ...View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021 ...

SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth …

In summary, Adaptive Biotechnologies Corp (ADPT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Adaptive Biotechnologies Corp ADPT Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation...Nov 2, 2023 · Stock. Stock Quote & Chart ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to …Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Adaptive Biotechnologies ...Adaptive’s layoffs come as a hot biotech IPO market during 2021 cools down and biotech stock values decline. One key biotech index fund, the SPDR S&P Biotech ETF (XBI), is down about 50% from ...Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ...

Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Adaptive Biotechnologies ...Get Adaptive Biotechnologies Corp (ADPT.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsAdaptive Biotechnologies Corp’s Stock Price as of Market Close. As of April 11, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.17. Adaptive Biotechnologies Corp is down 4.89% from its previous closing price of $8.59. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.33 and $8.61.Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued. View Adaptive Biotechnologies Corporation ADPT investment & stock information. Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock ...View Adaptive Biotechnologies Corporation ADPT investment & stock information. Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock ...

Adaptive Biotechnologies CEO on the company’s IPO and pipeline. Adaptive has agreed to spend a minimum of $12 million on Azure over seven years, according to its IPO prospectus, and Microsoft is ...

Get the latest Adaptive Biotechnologies Corporation (ADPT) stock news and headlines to help you in your trading and investing decisions. ... Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 ...Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Adaptive Biotechnologies Corp (NASDAQ: ADPT)’s stock price has soared by 3.44 in relation to previous closing price of 4.03. Nevertheless, the company has seen a gain of 18.77% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-09 that Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2023 Earnings Conference Call November 9, […]SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...The advantages of biotechnology include curing infectious diseases, creating more efficient fuels and increasing farming yields to feed more people. Disadvantages of biotechnology include antibiotic resistant bacteria, new allergic reaction...Adaptive Biotechnologies. Cathie Wood has bought almost 10 million shares of this stock for her Ark Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage ...Mar 9, 2023 · Shares of Adaptive Biotechnologies (ADPT) have gained 1.3% over the past four weeks to close the last trading session at $8.89, but there could still be a solid upside left in the stock if short ... 0.86%. $864.11M. ADPT | Complete Adaptive Biotechnologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...

SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

Adaptive Biotechnologies presently has a consensus target price of $9.50, suggesting a potential upside of 102.13%. Immatics has a consensus target price of $17.67, suggesting a potential upside of 96.08%. Given Adaptive Biotechnologies' higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Immatics.Interested individuals can access further details through the hyperlink provided by Adaptive Biotechnologies. Overall insider trading activity for Adaptive Biotechnologies has been noteworthy, with insiders recently selling 242,961 shares of the company’s stock. These transactions have amounted to a total value of $1,967,763.Jun 2, 2023 · As of June 02, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $7.46. Adaptive Biotechnologies Corp is up 5.82% from its previous closing price of $7.05. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $6.76 and $7.14. Currently, there are 143.51 million shares of Adaptive ... Adaptive Biotechnologies Corporation published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 10 January 2022 20:27:03 UTC .Phone Number (206) 659-0067. Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection …Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021 ...Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen closed nearly 83% …Sep 30, 2022 · 2022 Financial Guidance. Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 ... Phone Number (206) 659-0067. Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection …Adaptive Biotechnologies (NASDAQ:ADPT) has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $10.88 versus the current price of ...Adaptive Biotechnologies ( ADPT -9.24%) is a biotech-adjacent stock that peaked in January and then fell hard. It's down 61% from its high-water mark, but the average analyst on Wall Street thinks ...Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual ...

Watch Adaptive Biotechnologies stock price move in real-time ahead here. On February 14, Adaptive Biotechnologies will release earnings for the most recent quarter.Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20.Adaptive Biotechnologies Corp. ( NASDAQ: ADPT) stock is down over 72% in the previous 52-weeks and 58.5% YTD. Since its inception, the company has been a loss-maker. Still, the revenues have been ...Adaptive Biotechnologies. Wood has bought almost 10 million shares of this stock for her ARK Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage company ...Instagram:https://instagram. option strategies booknew nvidia cardsretiring to canadaclean energy stocks Dec 3, 2023 · 2009. 790. Chad Robins. https://www.adaptivebiotech.com. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions ... 0.86%. $864.11M. ADPT | Complete Adaptive Biotechnologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. investing in filmscan you paper trade crypto on webull Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Adaptive Biotechnologies ... dread mar conciertos 2023 Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Maneesh Tandon. Employment: Roche (I) Stock and Other Ownership Interests: Roche Pharma AG. Anna-Maria Fink. Research Funding: Celgene/Bristol Myers Squibb (Inst), AstraZeneca (Inst)How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding.Get a real-time Adaptive Biotechnologies Corporation (ADPT) stock price quote with breaking news, financials, statistics, charts and more. ... The 12-month stock ...